Clinical trials: Urinary System Tumor
Clear Cell Renal Cell Carcinoma
Prior Axitinib as a Determinant of Outcome of Renal Surgery
This is a single arm phase II study of axitinib in patients with clear cell renal cell carcinoma (RCC) with strong indications for partial nephrectomy (PN) for whom PN is not currently possible due to anatomic considerations and…
- Trial name
- PADRES (NCT03438708)
- Testing
- Axitinib Oral Tablet [Inlyta]
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Diego
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with…
- Trial name
- NCT06816017
- Testing
- Eciskafusp Alfa, BCG Medac Strain
- Where
- 9 sites in Australia, Italy and 4 more
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with…
- Trial name
- NCT03063762
- Testing
- Atezolizumab, Bevacizumab, RO6874281
- Where
- 23 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)
Phase II study (n=30) to evaluate the safety and feasibility of stereotactic body radiation therapy (SBRT) with fiducial markers in inoperable patients with renal cell carcinoma (RCC).
- Trial name
- ARREST (NCT02853162)
- Testing
- ARREST-study
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Renal Cell Cancer Metastatic, Kidney Cancer
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Fatigue is a prevalent adverse event associated with systemic therapy using tyrosine kinase inhibitors (TKIs). Meldonium, a fatty acid oxidation inhibitor, modifies the carnitine pathway, a nutrient critical for fat metabolism.
- Conditions
- Renal Cell Cancer Metastatic, Kidney Cancer, Fatigue Related to Cancer Treatment
- Trial name
- NCT06648902
- Testing
- meldonium
- Where
- 3 sites in Albania, Azerbaijan and 1 more
- Volunteers
- 60 people
- Sponsor
- Kidney Cancer Research Bureau
Bladder Cancer
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer (JaNEO).
- Trial name
- JaNEO (NCT02845050)
- Testing
- Vinflunine, Cisplatin, Radical cystectomy
- Where
- 2 sites in Germany
- Sponsor
- Ligartis GmbH
Lower Urinary Tract Symptoms, Bladder Carcinoma
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Common local side effects are generally seen during induction and during the first 6 months of BCG maintenance. BCG-related cystitis is frequent and unavoidable.
- Conditions
- Lower Urinary Tract Symptoms, Bladder Carcinoma, BCG
- Trial name
- NCT03549650
- Testing
- Pentosan Polysulfate Na 100Mg Cap
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Bladder Tumor
Endoscopic Resection of Bladder Tumors
To confirm the benefit of endoscopic resection under fluorescence and blue light of high grade non-muscle invasive bladder tumor, and verifying if the second endoscopic resection recommended nowadays can be deleted.
- Trial name
- NCT01750970
- Testing
- Endoscopic resection under blue light (Hexvix®)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Hopital Foch
Urinary Bladder Cancer, Urinary Bladder Neoplasm
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to…
- Conditions
- Urinary Bladder Cancer, Urinary Bladder Neoplasm, BCG, Trans Urethral Resection of a Bladder Tumor
- Trial name
- NCT05946369
- Testing
- Neutrophil to lymphocyte ratio
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Ain Shams University
Bladder Cancer
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
There is no consensus on the need for lymph node dissection in radical cystectomy (RC) for high-risk non-muscular invasive bladder cancer (NMIBC).
- Trial name
- PLND-Less (NCT05123625)
- Testing
- Reduce surgical procedures
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Renal Cell Carcinoma, Metastatic Disease
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
The purpose of this study is to see if preoperative administration of Sorafenib reduces the size of the primary kidney tumour in patients with metastatic disease undergoing cytoreductive surgery.
- Trial name
- NCT00480389
- Testing
- Sorafenib
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- University Health Network, Toronto
Bladder Urothelial Carcinoma, TURBT
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, TURBT, Bladder Neoplasm, Cystoscopy
- Trial name
- NCT03138824
- Testing
- SPIES assisted TURBT, WLI assisted TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Bladder Cancer, Radiation Cystitis
Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer
To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.
- Trial name
- NCT07125924
- Testing
- Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.), Normal Saline (NS)
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Pediatric ALL
Quality of Life for Pediatric Urolithiasis
The aim of this study is to assess the quality of life (QoL) in pediatric patients with urinary stone disease.
- Trial name
- Elattar (NCT06092203)
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Lymphoma, Brain Neoplasms
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Background: The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells.
- Conditions
- Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma
- Trial name
- NCT01236586
- Testing
- RO4929097, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
The aim of the study is to determine the MTD of the combination of everolimus plus axitinib in solid tumors, especially RCC.
- Trial name
- EVAX (NCT01334073)
- Testing
- Axitinib plus everolimus
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Non-muscle Invasive Bladder Cancer (NMIBC)
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in recurrent intermediate risk NMIBC.
- Trial name
- PemBla (NCT03167151)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Oxford
Kidney Neoplasm
German National Registry for NSS
The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses.
- Trial name
- NCT04681690
- Testing
- No intervention, observation only.
- Where
- 5 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Association of Urologic Oncology (AUO)
Metastatic Renal Cell Carcinoma
Second Line Sorafenib After Pazopanib in Patients With RCC
Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for…
- Trial name
- SOAP (NCT02122003)
- Testing
- Sorafenib
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.